Alogliptin benzoate for management of type 2 diabetes.

摘要: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement the action endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well tolerated because their low risk hypoglycemia other adverse events. Moreover, with potential to improve beta cell function, core defect type 2 diabetes, becoming major component treatment diabetes. Alogliptin benzoate is newly developed, highly selective inhibitor which has been approved in many countries throughout world. Once-daily administration alogliptin as either monotherapy or combination therapy antidiabetic drugs potent glucose-lowering effect similar that weight gain. The cardiovascular safety this drug confirmed recent randomized controlled trial. This review summarizes efficacy alogliptin, discusses role